ensun logo
Locations
Company type
Result types
Industries
Employees
Founding year
Combined Therapeutics Logo

Combined Therapeutics

Robert Langer is a Massachusetts Institute of Technology (MIT) professor and an expert in biotechnology and engineering. Dan Anderson is a Massachusetts Institute of Technology (MIT) professor and an expert in nano-based drugs and cancer immunology. Pierre Matussiere has more than twenty years of experience as an investment banker for Société Générale, Citigroup and BNP Paribas, primarily out of London. Kevin McLaughlin is a finance and management executive with more than 40 years of experience in the biopharma and high-tech industries. Robert Ruffolo is the former president of research & development at Wyeth Pharmaceuticals and brings a wealth of experience in drug discovery and development. Paul Wotton is a serial entrepreneur and inventor with more than 30 years of experience in the biotech and pharma industries.

Quick overview

Cambridge, United States

Founded in 2016

11-50 Employees

Additional information

Working industry

Biotechnology

Type of company

-

Ownership structure

Privately Held

Locations

3 Locations

Specialised areas

Biotechnology

ESG score estimation

An estimation about the ESG values based on digital data and signals. Important: The ESG scores are only based on information about the country, not the actual company itself

Country:

United States


Overall risk estimation:

Low


ESG country scores

The ESG Data of countries are based on public sources

Environment

D

Grade (A-E)

View details

Social

A

Grade (A-E)

View details

Governance

A

Grade (A-E)

View details

Use Cases of Combined Therapeutics

Get insights into the use cases of Combined Therapeutics

UseCase: Combined Therapeutics

Use case

Combined Therapeutics

Combined Therapeutics is an emerging mRNA medicines company developing a unique modified mRNA platform to protect vulnerable populations from global infectious diseases as well as to cure cancer.

Headquarter of Combined Therapeutics

Combined Therapeutics operates in 3 countries around the world

City: Cambridge

State: Massachusetts

Country: United States

Locations of Combined Therapeutics

Get an overview of the locations of Combined Therapeutics

Location

Country

State

City

Headquarter

United States

Massachusetts

Cambridge

United Kingdom Office

United Kingdom

England

London

France Office

France

Ile-de-France

Paris

Frequently asked questions (FAQ) about Combined Therapeutics

Some frequent questions that have been asked about Combined Therapeutics

The company headquarter of Combined Therapeutics is located in Cambridge, Massachusetts, United States. Combined Therapeutics has subsidiaries in United Kingdom, France

As of the latest available information Combined Therapeutics has around 11-50 employees worldwide.

Combined Therapeutics was founded in 2016

The company Combined Therapeutics has it's main focus in the industries of Biotechnology

Competitors of Combined Therapeutics

Check out some interesting alternative companies to Combined Therapeutics

Cogent Biosciences's Logo

Cogent Biosciences

Cambridge, United States

101-250 Employees

2014

Sachs has 20 years of experience, including over 12 in industry. Ferrante is a medical oncologist who has served as a member of our board of directors since February 2018. Matthew Ros is the former Chief Executive Officer and Director of the Board at FORE Biotherapeutics. Shegog has more than 25 years of financial, operations, corporate strategy and compliance expertise in the biotechnology and pharmaceutical industries. Wong’s research, teaching, and clinical activities focus on understanding the genetic alterations driving lung tumor formation and the testing of new targeted and immune lung cancer therapies. Verstovsek is the United Energy Resources, Inc., Professor of Medicine and hematologist-oncologist at MD Anderson. Verstovsek is a global leader in myeloproliferative neoplasms (MPN) and the Founder/Director of the largest MPN Clinical Research Center worldwide. Ryan Corcoran is the Director of the Gastrointestinal Cancer Center Program and the Scientific Director of the Termeer Center for Targeted Therapy at the Massachusetts General Hospital Cancer Center.

Step Pharma's Logo

Step Pharma

Paris, France

1-10 Employees

2014

We are a group of like-minded, experienced executives, biotechnology entrepreneurs and drug developers who have come together to bring STP938 to the clinic as fast as possible, drawing on our prior experience of developing and commercialising life-saving treatments. Our vision is to redefine how cancer is treated and bring our targeted therapy to patients as soon as possible. Horwitz participates in several national, and international committees and consortiums dedicated to the understanding and advancement of treatment for T cell lymphoma. Ansell, MD, PhD is a consultant in the Division of Hematology, Department of Internal Medicine at Mayo Clinic. Jean-Pierre Bizzari, MD is a world-renowned oncology expert who served as Executive Vice-President, Group Head, and Clinical Oncology Development (U.S., Europe, and Asia/Japan) at Celgene from 2008 to 2015. Kapil Dhingra, MD has more than 30 years of experience in oncology clinical research and drug development within the biotechnology and pharmaceutical industries. Christophe Benoist is the Morton Grove-Rasmussen Professor of Immunology at Harvard Medical School. Professor Iain McInnes is one of the leading figures in global research into rheumatoid and psoriatic arthritis.

IO Biotech's Logo

IO Biotech

Copenhagen, Denmark

51-100 Employees

2015

Ahmad is a trained internist and clinical oncologist and brings over two decades of successful strategic clinical development, medical affairs, and marketing authorization expertise. Zocca brings more than 18 years of experience in the biotechnology field and has participated in the founding and co-founding of several biotech spinouts. Sullivan is a seasoned life sciences professional with more than 25 years of experience raising capital and building and managing corporate biotechnology and life sciences brands. Faulkner brings more than 25 years of technical operations, quality, and product launch experience within the biotechnology industry. Faulkner has experience in product development, manufacturing operations, supply chain, and commercialization of peptides, proteins, monoclonal antibodies, viruses, and combination products. Faulkner held senior roles at Homology Medicines as head of CMC management and external manufacturing, product operations lead for the Rare Disease Business Unit at Shire (Takeda), and spent over 15 years at Biogen involved in the development and commercialization of Avonex®, Tysabri®, and Tecfidera®. Dhingra is a medical oncologist and a physician-scientist with a proven track record in academic research, patient care, and drug development. Dhingra founded KAPital Consulting, LLC in 2008, a company dedicated to helping biotechnology, pharmaceutical, and diagnostic companies realize the clinical and commercial advances in oncology.

Verum Diagnostics Inc's Logo

Verum Diagnostics Inc

Atlanta, United States

1-10 Employees

2019

Founder & CSO Over 33 years of biotech experience with a unique blend of academic, clinical, and industry experience. Clinical hospital research positions Senior positions in biotechnology companies. CEO 33 years of industry experience in biotech management, commercial, operations, and research roles.

Portage Biotech's Logo

Portage Biotech

Old Toronto, Canada

1-10 Employees

1973

Our Mission: To identify and accelerate promising medicines that revolutionize treatment and quality of life for patients with cancer. We know quality science and leverage our team’s deep knowledge to create a viable product development strategy that supports commercial potential and company growth. Among our most notable projects is the early investment, formation and growth of Biohaven Pharmaceuticals, leading the Company to the second-largest IPO in 2017 and later its successful commercialization leading to acquisition by Pfizer for approximately $12 billion in 2022. Each platform in our pipeline yields multiple products, and those products are discussed with potential big pharma partners and selected for clinical development if they are differentiated and have a compelling product profile. Ian Walters has over 20 years of leadership and expertise in oncology/immunology drug development and specializes in the evaluation, prioritization and innovation of new therapies for the treatment of severe diseases. Robert has 24 years of experience in the pharmaceutical industry and is the former Head of Oncology Discovery Research at both Bristol-Myers Squibb and Janssen Pharmaceuticals, part of the Johnson & Johnson group of companies. Robert has 24 years of experience in the pharmaceutical industry and is the former Head of Oncology Discovery Research at both Bristol-Myers Squibb and Janssen Pharmaceuticals , part of the Johnson & Johnson group of companies. Steve Innaimo is a seasoned R&D expert who brings more than 25 years of experience in drug development from the large pharma, biotech and contract research organization sectors.

Nimbus Therapeutics's Logo

Nimbus Therapeutics

Cambridge, United States

11-50 Employees

2009

Erin has more than 20 years HR leadership experience across biotech, medical device, manufacturing and entertainment industries. Jean is a General Partner of Lightstone Ventures. Mark Iwicki has 25 years of experience as a pharmaceutical industry leader managing all stages of drug development and commercialization in multiple therapeutic areas for several high-performance companies. Mark is the Chairman and CEO of Kala Pharmaceuticals and previously was CEO of Civitas Therapeutics which was sold to Acorda Therapeutics in 2014. Katharine Knobil has more than 20 years of experience in the pharmaceutical industry including global clinical research, medical affairs, and patient safety across both big pharma and smaller biotechnology companies. Vlasuk is a scientifically trained executive with nearly 40 years of leadership experience in drug discovery and development at small and large biotechnology and pharmaceutical companies. George is the author of more than 100 peer-reviewed scientific publications, book chapters and reviews, and 38 issued U.S.